Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
January 06 2021 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that Mike Sherman, Chief
Executive Officer, will participate in a pre-recorded presentation
at the H.C. Wainwright BioConnect 2021 Conference made available on
Monday, January 11, 2021 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the
Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound
derived from porcine heparin that, compared to commercially
available forms of heparin, may be dosed at higher levels without
associated bleeding-related complications. DSTAT is being studied
in a Phase 2/3 trial to assess safety and efficacy in adults with
acute lung injury with underlying COVID-19. A Phase 3 trial
protocol to study DSTAT in acute myeloid leukemia has been
developed in alignment with the US Food and Drug Administration
(FDA) and the first patient visit is expected in early 2021. BCV is
an antiviral drug candidate developed as a potential medical
countermeasure for smallpox and is currently under review for
regulatory approval in the United States. For further information,
please visit the Chimerix website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things,
Chimerix’s ability to obtain regulatory approval for BCV; the
timing and receipt of a potential procurement contract for BCV in
smallpox; and the timing of enrollment in the DSTAT trial for AML.
Among the factors and risks that could cause actual results to
differ materially from those indicated in the forward-looking
statements are risks that BCV may not obtain regulatory approval
from the FDA or such approval may be delayed or conditioned; risks
that Chimerix will not obtain a procurement contract for BCV in
smallpox in a timely manner or at all; risks related to the timing
and conduct of the DSTAT trial for AML; risks that ongoing or
future trials may not be successful or replicate previous trial
results, or may not be predictive of real-world results or of
results in subsequent trials; risks and uncertainties relating to
competitive products and technological changes that may limit
demand for our drugs; risks that our drugs may be precluded from
commercialization by the proprietary rights of third parties; and
additional risks set forth in the Company's filings with
the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
CONTACT:Investor
Relations: Michelle
LaSpaluto919 972-7115ir@chimerix.com Will O’ConnorStern
Investor Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024